MAP Pharma updates on two Ph III programs

California, USA-based MAP Pharmaceuticals has updated investors on the progress of two current Phase III clinical programs.

Initial enrollment for a trial of the firm's Unit Dose Budesonide, for  children with asthma, completed in September 2008, and all patients have  now completed the treatment period. In the multicenter, randomized,  double-blind, placebo-controlled trial in around 360 children with  asthma, from 12 months to eight years of age, patients received either  0.25mg UDB, 0.135mg UDB or placebo twice a day over a 12-week treatment  period. The co-primary efficacy endpoints for the study are the change  in night-time and daytime composite symptom scores.